325 476
[11]
Haffner MC, Aryee MJ, Toubaji A, et al. Androgen-induced TOP2B- mediated double-strand breaks and prostate cancer gene rearran- gements. Nat Genet 2010;42:668–75.[12]
Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33–9.[13]
Schweizer MT, Antonarakis ES, Wang H, et al. Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study. Sci Transl Med 2015;7:269ra2.
[14]
Umekita Y, Hiipakka RA, Kokontis JM, Liao S. Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride. Proc Natl Acad Sci U S A 1996;93:11802–7.
[15]
Zhau HY, Chang SM, Chen BQ, et al. Androgen-repressed phenotype in human prostate cancer. Proc Natl Acad Sci U S A 1996;93:15152–7.
[16]
Chuu CP, Hiipakka RA, Fukuchi J, Kokontis JM, Liao S. Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice. Cancer Res 2005;65:2082–4.
[17]
Maffini MV, Geck P, Powell CE, Sonnenschein C, Soto AM. Mecha- nism of androgen action on cell proliferation: AS3 protein as a mediator of proliferative arrest in the rat prostate. Endocrinology 2002;143:2708–14.[18]
Chuu CP, Kokontis JM, Hiipakka RA, et al. Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer. J Biomed Sci 2011;18:63.[19]
Kokontis JM, Lin HP, Jiang SS, et al. Androgen suppresses the proliferation of androgen receptor-positive castration-resistant prostate cancer cells via inhibition of Cdk2, cyclinA, and Skp2. PLoS One 2014;9:e109170.[20]
Teply BA, Kachhap S, Eisenberger MA, Denmeade SR. Extreme response to high-dose testosterone in BRCA2- and ATM-mutated prostate cancer. Eur Urol 2017;71:499.
[21]
Cai C, He HH, Chen S, et al. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell 2011;20:457–71.
[22]
Hedayati M, Haffner MC, Coulter JB, et al. Androgen deprivation followed by acute androgen stimulation selectively sensitizes AR- positive prostate cancer cells to ionizing radiation. Clin Cancer Res 2016;22:3310–9.
[23]
Denmeade S, Antonarakis E, Paller C, et al. A phase II study of rapid cycling high dose testosterone (bipolar androgen therapy) in men with metastatic castrate-resistant prostate cancer (mCRPC) resis- tant to abiraterone and/or enzalutamide. Eur J Cancer 2016;69(Suppl 1):S15.
[24]
Schiff JP, Lewis BE, Ledet EM, Sartor O. Prostate-specific antigen response and eradication of androgen receptor amplification with high-dose testosterone in prostate cancer. Eur Urol 2017; 71:997–8.
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 3 2 3 – 3 2 5
325